Omnicell, Inc. (OMCL): Price and Financial Metrics

Omnicell, Inc. (OMCL): $146.50

4.66 (+3.29%)

POWR Rating

Component Grades














  • OMCL scores best on the Growth dimension, with a Growth rank ahead of 99.04% of US stocks.
  • The strongest trend for OMCL is in Growth, which has been heading up over the past 31 weeks.
  • OMCL ranks lowest in Momentum; there it ranks in the 49th percentile.

OMCL Stock Summary

  • With a price/earnings ratio of 182.79, OMNICELL Inc P/E ratio is greater than that of about 95.81% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for OMNICELL Inc is higher than 82.47% of stocks in our set with a positive cash flow.
  • With a year-over-year growth in debt of 959.92%, OMNICELL Inc's debt growth rate surpasses 98.31% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to OMNICELL Inc, a group of peers worth examining would be ELF, HCKT, ENV, STMP, and IIPR.
  • OMCL's SEC filings can be seen here. And to visit OMNICELL Inc's official web site, go to

OMCL Valuation Summary

  • OMCL's price/earnings ratio is 185.5; this is 370.81% higher than that of the median Technology stock.
  • OMCL's price/sales ratio has moved up 4.7 over the prior 243 months.
  • Over the past 243 months, OMCL's EV/EBIT ratio has gone up 167.9.

Below are key valuation metrics over time for OMCL.

Stock Date P/S P/B P/E EV/EBIT
OMCL 2019-03-14 4.4 5.1 91.5 79.3
OMCL 2014-03-19 2.9 3.2 45.9 28.2
OMCL 2013-09-17 2.4 2.5 38.8 22.0
OMCL 2009-02-04 1.0 1.1 10.5 5.2
OMCL 2007-04-23 4.1 7.0 60.8 51.0
OMCL 2006-10-24 3.9 7.3 82.9 74.7

OMCL Growth Metrics

  • Its year over year net income to common stockholders growth rate is now at -49.53%.
  • The 3 year revenue growth rate now stands at 49.67%.
  • Its year over year cash and equivalents growth rate is now at 426.57%.
Over the past 49 months, OMCL's revenue has gone up $242,192,000.

The table below shows OMCL's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 914.365 218.054 35.01
2020-12-31 892.208 185.87 32.194
2020-09-30 891.298 144.242 37.912
2020-06-30 906.404 163.983 49.09
2020-03-31 924.196 143.742 69.365
2019-12-31 897.027 145.008 61.338

OMCL Price Target

For more insight on analysts targets of OMCL, see our OMCL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $156.67 Average Broker Recommendation 1.5 (Moderate Buy)

OMCL Stock Price Chart Interactive Chart >

Price chart for OMCL

OMCL Price/Volume Stats

Current price $146.50 52-week high $154.92
Prev. close $141.84 52-week low $66.04
Day low $140.58 Volume 307,800
Day high $147.33 Avg. volume 326,395
50-day MA $145.77 Dividend yield N/A
200-day MA $126.66 Market Cap 6.33B

Omnicell, Inc. (OMCL) Company Bio

Omnicell provides automation and business analytics software for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. The company was founded in 1992 and is based in Mountain View, California.

OMCL Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$146.50$99.52 -27%

Below please find a table outlining a discounted cash flow forecast for OMCL, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that OMNICELL Inc ranked in the 47th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 26.33%. The most interesting components of our discounted cash flow analysis for OMNICELL Inc ended up being:

  • The compound growth rate in the free cash flow of OMNICELL Inc over the past 5.75 years is 0.34%; that's higher than 66.52% of free cash flow generating stocks in the Technology sector.
  • The business' balance sheet suggests that 8% of the company's capital is sourced from debt; this is greater than just 23.49% of the free cash flow producing stocks we're observing.
  • OMNICELL Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of OMNICELL Inc? See GDDY, SVMK, DOCU, TTEC, and UI.

OMCL Latest News Stream

Event/Time News Detail
Loading, please wait...

OMCL Latest Social Stream

Loading social stream, please wait...

View Full OMCL Social Stream

Latest OMCL News From Around the Web

Below are the latest news stories about OMNICELL Inc that investors may wish to consider to help them evaluate OMCL as an investment opportunity.

Omnicell, inc (OMCL) Q2 2021 Earnings Call Transcript

OMCL earnings call for the period ending June 30, 2021.

Yahoo | July 31, 2021

Omnicell (OMCL) Q2 Earnings Top Estimates, 2021 EPS View Up

Omnicell (OMCL) reports better-than-expected revenues on strong segmental performance driving the top line in second-quarter 2021.

Yahoo | July 30, 2021

Spartanburg Regional Healthcare System partners with Omnicell

Omnicell (NASDAQ:OMCL) has announced that Spartanburg Regional Healthcare System, a long-time Omnicell partner, has selected the Co.’s industry-leading medication management platform to enhance efficiency, control, and safety across the care continuum. This combination of intelligence, automation, and technology-enabled services is designed to provide comprehensive inventory visibility from the central pharmacy...

Seeking Alpha | July 29, 2021

Omnicell (OMCL) Tops Q2 Earnings and Revenue Estimates

Omnicell (OMCL) delivered earnings and revenue surprises of 21.25% and 2.07%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 29, 2021

Spartanburg Regional Healthcare System Partners with Omnicell to Drive Improved Clinical and Operational Outcomes

MOUNTAIN VIEW, Calif., July 29, 2021--Spartanburg Regional Healthcare System Partners with Omnicell to Drive Improved Clinical and Operational Outcomes

Yahoo | July 29, 2021

Read More 'OMCL' Stories Here

OMCL Price Returns

1-mo -2.18%
3-mo 5.45%
6-mo 16.20%
1-year 108.42%
3-year 147.88%
5-year 286.24%
YTD 22.06%
2020 46.87%
2019 33.44%
2018 26.27%
2017 43.07%
2016 9.07%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8449 seconds.